Science and Technology Innovation Board Daily: Newpulse Medical sprints to be listed in Hong Kong stock market in artificial heart valve patent application and ranks 11th in the world

The artificial heart valve interventional therapy research and development company Newpulse Medical sprints for an IPO on the Hong Kong Stock Exchange.

Shanghai Newpulse Medical Technology Co.

New Pulse Medical is an innovative heart valve device company established in China in March 2015

Founded in 2015, Shanghai New

In addition, Newpulse Medical has also built a huge patent portfolio, aiming at the forefront of technology based on technological innovation and research and development

Newpulse Medical's R&D ranking in the professional field ranks among the top in the world

According to the company’s official website, New Pulse currently has 16 products under development, including four human heart valves: aortic valve, mitral valve, tricuspid valve and pulmonary valve.

From the prospectus of Newpulse Medical, it is known that the company's research products will be submitted for registration in the next few years (see Figure 1).

In the field of artificial heart valve interventional therapy, New Pulse Medical insists on being at the forefront of technology research and development.

With a solid technical foundation, New Pulse Medical has been favored and concerned by many investment companies

Newpulse Medical also attaches great importance to intellectual property rights.

A patent is a materialized presentation of the degree of technological innovation

According to the prospectus of Newpulse Medical, after the listing, the company plans to use more than 40% of the funds for the research and development, clinical trials and commercialization of the main research products (including Mi-thos, Valveclip-M and Valveclip-T); 42% of the funds are used for the research and development, clinical trials and commercialization of Prizvalve, the core product of Numerology

The effect of market policy is gradually showing

According to the research statistics of Guosen Securities, in 2018, there were about 209 million patients with heart valve disease in the world, causing about 2.
6 million deaths each year; domestically, according to the data disclosed in the New Pulse prospectus, in 2020, there will be more than 20 million people suffering from valve heart disease in China.
In recent years, given the advantages of low invasiveness and quick recovery, interventional cardiovascular therapy has gradually become a potential clinical option
.

According to the report of Guanyan Tianxia, ​​the market size of China's artificial heart valve industry in 2018 was 860 million yuan, an increase of 8.
9% over the previous year.
It is expected that by 2022, the market size of China's artificial heart valve industry will reach 1.
25 billion yuan
.
According to public information, about 125,000 cases of TAVR (transcatheter aortic valve replacement) were performed worldwide in 2018, and the global TAVR market was about US$3.
75 billion.
In 2025, the number of TAVR cases worldwide will reach 289,000.
Under further catalysis, it is expected that the final space of TAVR will reach 10-15 billion US dollars.
Combined with the innovation of transcatheter mitral valve, tricuspid valve, and pulmonary valve repair and replacement technology, it is predicted that the entire transcatheter heart valve market space will exceed 30 billion US dollars
.

With the continuous growth of market demand, the research and development of artificial heart valve-related technologies has shown a significant upward trend
.
From the perspective of patents, according to the "Technical Insights Briefing in the Field of Artificial Heart Valves" released by Wisdom Buds, there are about 15,000 patents in the field of artificial heart valve technology worldwide, and this field has shown a trend of accelerating applications in the past 20 years
.

It is worth noting that China ranks second in the world in the number of patent applications in the field of artificial heart valve related technologies, second only to the United States
.
The reason is that, in addition to being related to the growth of market demand, policy support also plays an important role
.
Since 2014, the Chinese government has issued many important documents in the field of innovative medical devices, in order to improve the innovation capability of domestic medical devices, break the monopoly of imported medical devices, increase the market share of domestic medical devices, and further enhance the level of industrialization
.
Then, in October 2017, the General Office of the Central Committee of the Communist Party of China jointly issued the "Opinions on Deepening the Reform of the Review and Approval System and Encouraging the Innovation of Drugs and Medical Devices", proposing that " artificial heart valves as innovative medical devices will be a key industry for national development "
.
The vigorous support of national policies has promoted the continuous warming of technology research and development
.
Judging from the trend of patent applications between China and the United States, the gap in the number of related patent applications between China and the United States in recent years is gradually narrowing
.

In this context, whether Newpulse Medical can take advantage of the market and policies to successfully go public has received widespread attention
.

Original link: https://api3.
cls.
cn/share/article/956118?app=stib&os=android&sv=214